Taken together, our results demonstrated that blocking CXCL1 signaling during acute HEVA71 infection can be an effective therapeutic approach to manage the effects of neuropathogenicity in severe cases of HFMD. This evidence concerns the gene CXCL1 and hand, foot and mouth disease.